Needham raised the firm’s price target on I-Mab (IMAB) to $6 from $5 and keeps a Buy rating on the shares. Givastomig dose expansion results remain on track for 1Q26 and will help determine next steps for the program, the analyst tells investors in a research note. The firm also believes recent financing removes a potential overhang from the stock and raised its price target to reflect increased value for givastomig.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMAB:
- I-MAB’s Positive Outlook: Buy Rating Backed by Financial Stability and Promising Clinical Developments
- I-Mab Reports Strong Financials and Clinical Progress in August 2025
- I-Mab reports Q2 EPS (3c), consensus (5c)
- I-Mab sees cash runway through 4Q28
- I MAB (ADS) options imply 11.8% move in share price post-earnings